Safety Recall: Bic Trading Acropass TBC – Japan CAA

Published by Reclia Safety Desk | June 29, 2026

Recall Information Record

Case Number: 00000035392
Product: Acropass TBC
Brand: Bic Trading
Hazards: Safety Risk
Source: Japan Consumer Affairs Agency (CAA)

WHAT HAPPENED

Bic Trading has issued a recall for its product ‘Acropass TBC’ (Japanese: アクロパス TBC) due to critical labeling and regulatory compliance issues. The Japan Consumer Affairs Agency (CAA) recall notice (ID: 00000035392) reports that the product’s sales name was incorrectly displayed as ‘Acropass Trouble Cure’ instead of the correct name ‘Acropass TBC’. Additionally, the product’s labeling included efficacy and effect claims that exceeded the scope approved by regulatory authorities.

This mislabeling and unauthorized claim expansion pose significant risks to consumer safety and regulatory compliance. Incorrect product names may lead to consumer confusion or misuse, while unapproved efficacy claims could mislead users about the product’s actual benefits and limitations. The recall underscores the importance of accurate labeling and adherence to approved marketing authorizations for medical and quasi-drug products in Japan.

Consumers who have purchased the affected product should take the following steps:

• Check the product packaging for the sales name ‘Acropass TBC’ and verify if it is incorrectly labeled as ‘Acropass Trouble Cure’.
• Discontinue use immediately if you have the mislabeled product.
• Contact Bic Trading using the contact information provided in the recall notice for instructions on return, refund, or replacement.
• Report any adverse effects or concerns to the PMDA (Pharmaceuticals and Medical Devices Agency) via their consumer reporting system.

AFFECTED BATCHES & TARGET SPECIFICS

– **Target Model / Type:** N/A
– **JAN Barcode:** N/A
– **Affected Serial / Lot Numbers:** N/A
– **Total Units Affected:** N/A

ADDITIONAL REGULATORY NOTES

The recall was initiated due to a mislabeling of the sales name (incorrectly labeled as ‘Acropass Trouble Cure’ instead of ‘Acropass TBC’) and display of efficacy/effect claims beyond the approved scope. The recall start date is June 10, 2026. Reference information is from PMDA. Management number: 00000035392.

❓ Frequently Asked Questions